Ironwood Pharmaceuticals | IRWD - Net Income


Ironwood Pharmaceuticals reported $3.19M in Net Income for its fiscal quarter ending in December of 2024.





Net Income Change Date
Acadia Pharmaceuticals USD 3.64M 269.93M Mar/2026
Agios Pharmaceuticals USD -99.11M 8.93M Mar/2026
Akebia Therapeutics USD -12.24M 12.78M Dec/2025
Almirall EUR 19.58M 7M Dec/2025
Alnylam Pharmaceuticals USD 205.99M 19.57M Mar/2026
Amarin USD -1.22M 6.51M Dec/2025
Ardelyx USD -407K 562K Dec/2025
Astellas Pharma JPY 43.52B 56.86B Mar/2026
AstraZeneca USD 3.08B 754M Mar/2026
Charles River Laboratories USD -14.84M 261.71M Mar/2026
Coherus Biosciences USD -37.64M 2.11M Dec/2025
Emergent BioSolutions USD -261.3M 78.3M Jun/2023
Esperion Therapeutics USD 61.83M 93.16M Dec/2025
Halozyme Therapeutics USD 150.05M 291.64M Mar/2026
Incyte USD 303.33M 4.05M Mar/2026
Ironwood Pharmaceuticals USD 3.19M 457K Dec/2024
Karyopharm Therapeutics USD -102.2M 71.42M Dec/2025
Lexicon Pharmaceuticals USD -15.53M 2.76M Dec/2025
MacroGenics USD -14.16M 30.98M Dec/2025
Moderna USD -1.34B 517M Mar/2026
Myriad Genetics USD -7.9M 19.5M Dec/2025
Pacira USD 2.92M 1.28M Mar/2026
PTC Therapeutics USD -2.81M 132.16M Mar/2026
Puma Biotechnology USD 20.32M 24.85M Sep/2024
Sarepta Therapeutics USD 330.96M 743.18M Mar/2026
Takeda JPY -24.32B 127.96B Mar/2026
Ultragenyx Pharmaceutical USD -185M 56M Mar/2026
Vanda Pharmaceuticals USD -18.9M 13.58M Dec/2024